Prospective Evaluation of <i>MGMT</i>-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Prospective Evaluation of <i>MGMT</i>-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin. The predictive role of MGMT-promoter methylation in this setting is controversial. We sought to pr...

Full description

Bibliographic Details
Main Authors: Nicole Brighi, Giuseppe Lamberti, Elisa Andrini, Cristina Mosconi, Lisa Manuzzi, Giada Donati, Andrea Lisotti, Davide Campana
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Current Oncology
Subjects:
neuroendocrine neoplasms
chemotherapy
biomarkers
epigenetic
gastroenteropancreatic
Online Access:https://www.mdpi.com/1718-7729/30/2/106

Similar Items

Similar Items